Figure 7.

Ankylosing spondylitis: improvement in disease activity. Infliximab sustains improvement in disease activity over 5 years. At 156 weeks, n = 43 patients; at 254 weeks, n = 38. ASAS, Assessment of SpondyloArthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; IFX, infliximab. Modified with permission from [74].

Smolen and Emery Arthritis Research & Therapy 2011 13(Suppl 1):S2   doi:10.1186/1478-6354-13-S1-S2